Form 4: Emergent BioSolutions Inc. (EBS), Fox Jennifer Lynne, transaction 03/01/2022

Summary

Fox Jennifer Lynne, an Emergent BioSolutions Inc. officer with the title EVP, Ext Aff, GC, Corp Sec, reports on this Form 4 grants dated 03/01/2022: 7,583 performance stock units, 17,794 restricted stock units and 26,584 Employee Stock Options (Right to Buy) at $41.38, expiring 02/28/2029. The PSUs vest on adjusted EBITDA as a percentage of total GAAP revenue over the three-year period beginning January 1, 2022 and ending December 31, 2024, reported at the target payout factor of 100%. The restricted stock units vest partly in three equal annual installments and partly on the day prior to the second anniversary date of the grant, assuming continued service with the company. The reporting person owned 32,627 shares directly afterward; the remarks show /s/ S. Scott Lieberman Attorney-In-Fact, dated 03/03/2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Fox Jennifer Lynne (Last) (First) (Middle) 400 PROFESSIONAL DRIVE SUITE 400 (Street) GAITHERSBURG MD 20879 (City) (State) (Zip) | Fox Jennifer Lynne | (Last) | (First) | (Middle) | 400 PROFESSIONAL DRIVE | SUITE 400 | GAITHERSBURG | MD | 20879 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [ EBS ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) EVP, Ext Aff, GC, Corp Sec | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | EVP, Ext Aff, GC, Corp Sec
3. Date of Earliest Transaction
 (Month/Day/Year) 03/01/2022
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 03/01/2022 | A | 7,583 (1) | A | $ 0 | 14,833 | D
Common Stock | 03/01/2022 | A | 17,794 (2) | A | $ 0 | 32,627 | D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Employee Stock Options (Right to Buy) | $ 41.38 | 03/01/2022 | A | 26,584 | (3) | 02/28/2029 | Common Stock | 26,584 | $ 41.38 | 26,584 | D
Explanation of Responses:
1. Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.
2. Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest either in three equal annual installments beginning on the day prior to the first anniversary of the date of grant (8,713 shares) or on the day prior to the second anniversary date of the grant (9,063 shares), assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
3. Vests in three equal installments beginning on the day prior to the anniversary date of the grant.
Remarks:
/s/ S. Scott Lieberman Attorney-In-Fact | 03/03/2022
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_EBS_4_filed2022-03-03_0001367644-22-000048.xml

Size

17,949 bytes

SHA-256

03fec73ce091c5be1801646f0a9e26ababae6e7ca85d701b1ea64f30b7797e1c

Our copy

SEC_EBS_4_filed2022-03-03_0001367644-22-000048.xml

Original

www.sec.gov